Latest news with #NadineMcGrath
Herald Sun
16-06-2025
- Business
- Herald Sun
Vital Signs Podcast: EBR's major milestones in WiSE CRT commercialisation
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to John McCutcheon, the President and CEO of EBR Systems (ASX:EBR). EBR is focused on its lead technology, the WiSE CRT System, an innovative device designed to overcome the limitations of conventional Cardiac Resynchronisation Therapy (CRT) and is the only leadless left ventricular endocardial pacing (LVEP) device on the market. The company recently received FDA approval for the device in the US, opening the door to a mega market opportunity in one of the worlds largest healthcare markets. Earlier this month, the first two US commercial patients were treated with WiSE ahead of the company's reimbursement milestones, further demonstrating the clinical importance of the device. In this episode McCutcheon explains the significance of the technology, the reimbursement scheme and outlines the next steps for EBR as it prepares for commercial roll out. This podcast was developed in collaboration with EBR Systems, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Vital Signs Podcast: EBR's major milestones in WiSE CRT commercialisation
Herald Sun
04-06-2025
- Business
- Herald Sun
Vital Signs: Compumedics
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical device company focused on diagnostic tech for sleep, brain and blood flow monitoring. Founded in 1987, Compumedics' strategy was initially focused on developing its core competency, Sleep Diagnostics. The company even set up Australia's first ever fully computerised sleep clinic. Today, Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, neuro diagnostics and ultrasonic blood flow monitoring, with products distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. This podcast was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Vital Signs Podcast: Breakthrough brain scanning technology overcoming diagnostic hurdles
The Australian
04-06-2025
- Business
- The Australian
Vital Signs: Compumedics
Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical device company focused on diagnostic tech for sleep, brain and blood flow monitoring. Founded in 1987, Compumedics' strategy was initially focused on developing its core competency, Sleep Diagnostics. The company even set up Australia's first ever fully computerised sleep clinic. Today, Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, neuro diagnostics and ultrasonic blood flow monitoring, with products distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. This podcast was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Mercury
04-06-2025
- Business
- Mercury
Vital Signs Podcast: Breakthrough brain scanning technology overcoming diagnostic hurdles
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical device company focused on diagnostic tech for sleep, brain and blood flow monitoring. Founded in 1987, Compumedics' strategy was initially focused on developing its core competency, Sleep Diagnostics. The company even set up Australia's first ever fully computerised sleep clinic. Today, Compumedics has evolved into one of the world's leading suppliers of medical technology for sleep, neuro diagnostics and ultrasonic blood flow monitoring, with products distributed to clients around the globe, helping millions of people who suffer from debilitating sleep, neurological and other healthcare problems. This podcast was developed in collaboration with Compumedics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Vital Signs Podcast: Breakthrough brain scanning technology overcoming diagnostic hurdles
